Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.37 |
| ▸ | KDM5A | P29375 | 4/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165840 | 0.90 | EP300 (0.40) | MEN1KMT2ACREBBPEP300ALDH1A1 | |
| SCHEMBL6164758 | 0.85 | CREBBP (0.37) | MEN1KMT2ACREBBPEP300PTGER1 | |
| SCHEMBL6622927 | 0.78 | HSD11B1 (0.42) | MEN1KMT2ACREBBPEP300HSD11B1 | |
| SCHEMBL4505041 | 0.77 | MEN1 (0.54) | MEN1KMT2ACREBBPEP300ALDH1A1 | |
| SCHEMBL6635699 | 0.77 | CREBBP (0.35) | KMT2ACREBBPEP300HSD11B1L3MBTL1 | |
| SCHEMBL6167484 | 0.77 | HSD11B1 (0.43) | CREBBPEP300HSD11B1ALDH1A1GAA | |
| SCHEMBL6165266 | 0.75 | GAA (0.40) | MEN1KMT2ACREBBPEP300ALDH1A1 | |
| SCHEMBL6165357 | 0.73 | HSD11B1 (0.40) | MEN1KMT2ACREBBPEP300HSD11B1 | |
| SCHEMBL6167571 | 0.72 | MEN1 (0.49) | MEN1KMT2ACREBBPEP300KDM4C | |
| SCHEMBL6611947 | 0.72 | MLLT3 (0.45) | MEN1KMT2ACREBBPEP300HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379511-B1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | EP | disclosed |
| EP-1379511-A1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
| WO-2002083652-A1 | DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | MEN1 1887/4885KMT2A 1244/4885CREBBP 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.